Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20804834 | 0.83 | DRD4 (0.56) | CHRNB2CHRNA4TRPV6SIGMAR1DRD4 | |
| SCHEMBL14892774 | 0.76 | DRD4 (0.59) | MEN1KMT2ACYP2D6GAASIGMAR1 | |
| SCHEMBL20798113 | 0.74 | CHRNB2 (0.56) | CHRNB2CHRNA4OPRM1OPRL1MEN1 | |
| SCHEMBL30057551 | 0.74 | CHRNB2 (0.56) | CHRNB2CHRNA4OPRM1OPRL1MEN1 | |
| SCHEMBL27798357 | 0.72 | SIGMAR1 (0.62) | MEN1KMT2ACYP2D6GAASIGMAR1 | |
| SCHEMBL25342293 | 0.71 | TRPV6 (0.43) | TRPV6GHSRCYP2D6SIGMAR1KDR | |
| SCHEMBL29457489 | 0.71 | TRPV6 (0.43) | TRPV6GHSRCYP2D6SIGMAR1KDR | |
| SCHEMBL31458771 | 0.69 | CYP2D6 (0.55) | CHRNB2CHRNA4TRPV6GHSRMEN1 | |
| SCHEMBL20798157 | 0.69 | CHRM4 (0.47) | OPRM1MEN1KMT2APARP1PARP2 | |
| SCHEMBL1426883 | 0.68 | KCNH2 (0.47) | MEN1KMT2ACYP2D6KCNH2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | Neumora Therapeutics, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-3679043-B9 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3679043-B1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | NEUMORA THERAPEUTICS INC (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-111212842-B | Vasopressin receptor antagonists and products and methods related thereto | 布莱克索恩治疗公司 | 2022-10-25 | — | — | CN | disclosed |
| US-20210317126-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210317126-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-3679043-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Blackthorn Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2019050988-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019050988-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152038-B2 | Vasopressin receptor antagonists and products and methods related thereto | AVPR1A, AVPR2, AVPR1B | CHRNB2 1338/4885CHRNA4 1119/4885OPRM1 110/4885 |
| US-20210317126-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1A, AVPR2, AVPR1B | CHRNB2 1338/4885CHRNA4 1119/4885OPRM1 110/4885 |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1A, AVPR2, AVPR1B | CHRNB2 1338/4885CHRNA4 1119/4885OPRM1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.